Jump to contentThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged inAllNewsSportCultureLifestylePharmaceutical giant GSK has announced plans to close its main research and development hub in Stevenage, Hertfordshire.GSK intends for its new 300,000 sq ft Cambridge centre to house over 1,000 scientists.This strategic move is part of a broader initiative to achieve £1.9 billion in cost savings over three years, with £400 million invested in facilitating these changes. Staff currently based in Stevenage will be moved to the company's upgraded Ware site, with GSK hoping all Stevenage workers will relocate to either Cambridge or Ware.The cost savings are earmarked to fund increased R&D efforts and help offset the financial impact when one of its key HIV treatments, dolutegravir, loses its patent protection. In fullPharma giant GSK to relocate research headquarters to Cambridge in £400m moveMore bulletinsThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in
GSK announces plans to close main research hub in Stevenage
Jump to contentThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged inAllNewsSportCultureLifestylePharmaceutical giant GSK has announced plans to close its main research and development hub in Stevenage, Hertfordshire.GSK intends for its new 300,000 sq ft Cambridge centre to house over 1,000 scientists.This strategic move is part of a broader initiative to achieve £1.9 billion in cost savings over three years, with £400 million invested in facilitating these changes. Staff currently based in Stevenage will be moved to the company's upgraded Ware site, with GSK hoping all Stevenage workers will relocate to either Cambridge or Ware.The cost savings are earmarked to fund increased R&D efforts and help offset the financial impact when one of its key HIV treatments, dolutegravir, loses its patent protection. In fullPharma giant GSK to relocate research headquarters to Cambridge in £400m moveMore bulletinsThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in
